Learning about CIBINQO for treating atopic dermatitis
Special Investigation for CIBINQO （Long Term）
This study is testing how safe and effective the medication CIBINQO is for people with atopic dermatitis in Japan, whether they are starting it for the first time or continuing after a hospital transfer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Tokyo) |
| Trial ID | NCT05387980 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety and effectiveness of CIBINQO, a JAK inhibitor, in individuals with atopic dermatitis under Japanese medical practice. Participants will either be starting treatment with CIBINQO for the first time or continuing treatment after a hospital transfer. The study will gather data on how well the medication works and its safety profile in real-world settings.
Who should consider this trial
Good fit: Ideal candidates are individuals receiving CIBINQO for the treatment of atopic dermatitis.
Not a fit: Patients who have previously participated in this study at the same site will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of CIBINQO for managing atopic dermatitis.
How similar studies have performed: Other studies involving JAK inhibitors for atopic dermatitis have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants receiving this Product for treatment of AD. 2. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively. Exclusion Criteria: 1. Participants previously enrolled in this Study at the same site.
Where this trial is running
Tokyo
- Pfizer Local Country Office — Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.